Cambridge, UK, August 21st 2018 — Prosarix UK Ltd announces today that it has completed an asset purchase and licensing agreement with Evolva to once again operate as a standalone company trading under the name ‘Prosarix’. The original Prosarix Ltd was acquired in 2014 to strengthen Evolva’s in-house in silico capabilities.
Prosarix UK will now be dedicated to providing contract research services to both the pharmaceutical and biotechnology sectors using its advanced small molecule design technology ProtoDiscovery which has been used in many successful projects with client companies since 2007. William Hamilton, CEO of Prosarix said ‘We have taken the opportunity to spin-out the Prosarix technology into a company dedicated to providing leading computational chemistry services. We now look to build on our strong track record in this field and provide first in class methods and approaches’.